mmw
☆    

India,
2016-06-23 10:06
(2836 d 07:00 ago)

Posting: # 16448
Views: 2,201
 

 Iron Sucrose [Regulatives / Guidelines]

Dear All,

There are many more discussions are available on clinical development for generic version of Iron Sucrose Injection. EMA and FDA has different approaches regarding BE study of Iron Sucrose Injection.

According to the FDA's present draft guidance on Iron Sucrose, bioequivalence should be based on "Maximum value of the difference in concentration between Total Iron and Transferrin-bound Iron over all time points measure."

Could anyone please elaborate FDAs thinking behind this criteria for evaluation?

Thanks in advance

MMW


Edit: Guidance linked; see also this post #3. [Helmut]
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
113 visitors (0 registered, 113 guests [including 7 identified bots]).
Forum time: 16:06 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5